NEW: Premarket Now Starts at 4AM!

We’re excited to announce the extension of premarket and aftermarket hours! Our members now have access to quotes daily from 4:00 AM to 8:00 PM ET — offering greater flexibility and deeper insights into market trends beyond regular trading hours.

Upgrade to FINVIZ*Elite to access premarket quotes »

Open in Screener

EXEL

Exelixis Inc

May 23 • 02:08PM ET

42.48

Dollar change -0.38
Percentage change -0.90	%

Healthcare • Biotechnology • USA • NASD

Peers: REGN AMGN GILD VRTX BIIB BMRN INCY ALNY NBIX IONS

| Held by: IJH VTI VB VXF VBK XBI MDY XMHQ IBB IJK

Index	-	P/E	19.27	EPS (ttm)	2.20	Insider Own	3.31%	Shs Outstand	275.03M	Perf Week	-6.44%
Market Cap	11.58B	Forward P/E	14.29	EPS next Y	2.97	Insider Trans	-8.19%	Shs Float	263.68M	Perf Month	14.15%
Income	643.57M	PEG	0.61	EPS next Q	0.60	Inst Own	93.07%	Short Float	7.28%	Perf Quarter	14.40%
Sales	2.30B	P/S	5.04	EPS this Y	40.40%	Inst Trans	3.30%	Short Ratio	6.40	Perf Half Y	23.44%
Book/sh	7.75	P/B	5.48	EPS next Y	20.28%	ROA	22.82%	Short Interest	19.18M	Perf Year	102.07%
Cash/sh	3.78	P/C	11.23	EPS next 5Y	31.52%	ROE	30.22%	52W Range	20.14 - 48.85	Perf YTD	27.55%
Dividend Est.	-	P/FCF	14.11	EPS past 5Y	11.55%	ROI	27.76%	52W High	-13.05%	Beta	0.28
Dividend TTM	-	Quick Ratio	3.44	Sales past 5Y	18.34%	Gross Margin	96.78%	52W Low	110.90%	ATR (14)	1.71
Dividend Ex-Date	-	Current Ratio	3.50	EPS Y/Y TTM	244.87%	Oper. Margin	35.43%	RSI (14)	59.09	Volatility	0.52% 4.89%
Employees	1147	Debt/Eq	0.09	Sales Y/Y TTM	24.49%	Profit Margin	27.99%	Recom	1.95	Target Price	40.89
Option/Short	Yes / Yes	LT Debt/Eq	0.09	EPS Q/Q	353.64%	Payout	0.00%	Rel Volume	0.51	Prev Close	42.86
Sales Surprise	11.18%	EPS Surprise	70.89%	Sales Q/Q	30.62%	Earnings	May 13 AMC	Avg Volume	3.00M	Price	42.48
SMA20	4.99%	SMA50	11.77%	SMA200	27.38%	Trades		Volume	1,100,263	Change	-0.90%

Date	Action	Analyst	Rating Change	Price Target Change
Feb-24-25	Downgrade	Wells Fargo	Overweight → Equal Weight	$36
Jan-27-25	Upgrade	Morgan Stanley	Equal-Weight → Overweight	$30 → $40
Jan-24-25	Downgrade	Oppenheimer	Outperform → Perform
Dec-20-24	Downgrade	BMO Capital Markets	Outperform → Market Perform	$36 → $40
Dec-17-24	Downgrade	BofA Securities	Buy → Neutral	$35 → $39
Oct-16-24	Reiterated	RBC Capital Mkts	Outperform	$30 → $34
Sep-19-24	Initiated	UBS	Neutral	$30
Apr-11-24	Downgrade	Barclays	Overweight → Equal Weight	$25
Dec-19-23	Initiated	BTIG Research	Buy	$27
Dec-15-23	Initiated	Citigroup	Buy	$31
Sep-26-23	Initiated	H.C. Wainwright	Buy	$28
Aug-22-23	Reiterated	Oppenheimer	Outperform	$25 → $29
Aug-08-23	Initiated	SVB Securities	Market Perform	$18
Jul-11-23	Resumed	Morgan Stanley	Equal-Weight	$21
May-10-23	Resumed	Piper Sandler	Overweight	$28
Mar-09-23	Initiated	Wells Fargo	Overweight	$23
Jan-26-23	Initiated	Credit Suisse	Outperform	$29
Oct-18-22	Initiated	JMP Securities	Mkt Outperform	$26
Jun-24-22	Initiated	BMO Capital Markets	Outperform	$28
Nov-19-21	Initiated	Piper Sandler	Overweight	$34

Show Previous Ratings

Today 11:40AM	EXEL vs. ARGX: Which Stock Is the Better Value Option? (Zacks)
09:57AM	EXEL Reports Superior Efficacy Data From Kidney Cancer Study Cohort (Zacks)
06:25AM	Product Performance, Big Money Lift Exelixis (FX Empire)
May-22-25 05:17PM	Exelixis Announces Encouraging Results from Phase 1b/2 STELLAR-002 Trial Evaluating Zanzalintinib in Combination with Immune Checkpoint Inhibitors in Advanced Kidney Cancer at ASCO 2025 (Business Wire)
04:05PM	Exelixis to Webcast Fireside Chats as Part of Upcoming Investor Conferences in May and June (Business Wire)
03:07PM	Loading…
May-19-25 03:07PM	ACADIA Pharmaceuticals Stock Sees RS Rating Jump To 93 (Investor's Business Daily)
12:00PM	Exelixis (EXEL) is a Great Momentum Stock: Should You Buy? (Zacks)
09:50AM	Are You a Momentum Investor? This 1 Stock Could Be the Perfect Pick (Zacks)
09:15AM	Unlocking Exelixis (EXEL) International Revenues: Trends, Surprises, and Prospects (Zacks)
May-15-25 09:45AM	Why Exelixis (EXEL) is a Top Growth Stock for the Long-Term (Zacks)
09:42AM	Company News for May 15, 2025 (Zacks)
May-14-25 07:56PM	Why Exelixis, Inc. (EXEL) Skyrocketed On Wednesday (Insider Monkey) +20.84%
04:42PM	These Stocks Moved the Most Today: Nvidia, AMD, Super Micro, UnitedHealth, eToro, Oklo, Exelixis, and More (Barrons.com)
03:05PM	These Stocks Are Moving the Most Today: Nvidia, AMD, Super Micro, UnitedHealth, eToro, Oklo, Exelixis, and More (Barrons.com)
02:22PM	eToro's Nasdaq debut, Exelixis outlook, SepternaNovo deal (Yahoo Finance Video)
11:33AM	Loading…
11:33AM	Why Exelixis Stock Is Skyrocketing Today (Motley Fool)
09:00AM	EXEL Q1 Earnings Beat, 2025 Sales View Up as Cabometyx Drives Top Line (Zacks)
08:40AM	Q1 2025 Exelixis Inc Earnings Call (Thomson Reuters StreetEvents)
03:18AM	Exelixis Inc (EXEL) Q1 2025 Earnings Call Highlights: Strong Revenue Growth and Strategic ... (GuruFocus.com)
May-13-25 06:06PM	Invenra Highlights Exelixis' Initiation of Phase 1 Clinical Study Evaluating XB628, a First-in-Class Bispecific Antibody in Participants with Recurrent Advanced or Metastatic Solid Tumors (Business Wire)
06:00PM	Exelixis (EXEL) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates (Zacks)
05:20PM	Exelixis (EXEL) Surpasses Q1 Earnings and Revenue Estimates (Zacks)
04:23PM	Exelixis: Q1 Earnings Snapshot (Associated Press Finance)
04:19PM	Biotech Leader Exelixis Pops After Obliterating First-Quarter Profit Expectations (Investor's Business Daily)
04:07PM	Exelixis Announces First Quarter 2025 Financial Results and Provides Corporate Update (Business Wire)
May-12-25 12:10PM	Will Exelixis (EXEL) Beat Estimates Again in Its Next Earnings Report? (Zacks)
09:40AM	Are You a Value Investor? This 1 Stock Could Be the Perfect Pick (Zacks)
09:15AM	Urogen Pharma (URGN) Reports Q1 Loss, Lags Revenue Estimates (Zacks)
May-11-25 04:52PM	Is Exelixis, Inc. (EXEL) One of the Best Stocks to Buy According to Jim Simons' Renaissance Technologies? (Insider Monkey)
May-08-25 05:10PM	Celldex Therapeutics (CLDX) Reports Q1 Loss, Lags Revenue Estimates (Zacks)
09:15AM	Loading…
09:15AM	Ahead of Exelixis (EXEL) Q1 Earnings: Get Ready With Wall Street Estimates for Key Metrics (Zacks)
May-07-25 04:05PM	Exelixis to Webcast Fireside Chats as Part of Investor Conferences in May (Business Wire)
May-03-25 02:47PM	Exelixis, Inc. (EXEL): Among the Large-Cap Stocks Insiders and Short Sellers Are Dumping Like Crazy (Insider Monkey)
May-02-25 09:50AM	Here's Why Exelixis (EXEL) is a Strong Momentum Stock (Zacks)
Apr-29-25 04:05PM	Exelixis to Release First Quarter 2025 Financial Results on Tuesday, May 13, 2025 (Business Wire)
09:45AM	Are You a Growth Investor? This 1 Stock Could Be the Perfect Pick (Zacks)
06:42AM	Can Amgen Keep the Beat Streak Alive This Earnings Season? (Zacks)
Apr-26-25 08:00AM	MercadoLibre, The Amazon Of Latin America, Leads Five Stocks Near Buy Points (Investor's Business Daily)
Apr-25-25 01:29PM	Exelixis' Q1 Earnings: Will Cabometyx Maintain Momentum? (Zacks)
Apr-24-25 10:02AM	Earnings Preview: Alkermes (ALKS) Q1 Earnings Expected to Decline (Zacks)
09:40AM	Here's Why Exelixis (EXEL) is a Strong Value Stock (Zacks)
Apr-22-25 10:01AM	Exelixis (EXEL) Earnings Expected to Grow: What to Know Ahead of Q1 Release (Zacks)
Apr-20-25 11:28AM	IDNA: The Cutting Edge Of Medical Science Is A Risky Investment (Seeking Alpha)
Apr-16-25 09:50AM	Why Exelixis (EXEL) is a Top Momentum Stock for the Long-Term (Zacks)
06:20AM	Is First Trust Mid Cap Core AlphaDEX ETF (FNX) a Strong ETF Right Now? (Zacks)
Apr-14-25 06:20AM	Should First Trust Mid Cap Core AlphaDEX ETF (FNX) Be on Your Investing Radar? (Zacks)
Apr-11-25 12:10PM	Will Exelixis (EXEL) Beat Estimates Again in Its Next Earnings Report? (Zacks)
09:45AM	Why This 1 Growth Stock Could Be a Great Addition to Your Portfolio (Zacks)
Apr-10-25 03:30PM	Harbor Mid Cap Value Fund Q4 2024 Commentary (Seeking Alpha)
06:20AM	Should John Hancock Multifactor Small Cap ETF (JHSC) Be on Your Investing Radar? (Zacks)
Apr-08-25 09:40AM	Why Exelixis (EXEL) is a Top Value Stock for the Long-Term (Zacks)
Apr-07-25 06:20AM	Is John Hancock Multifactor Small Cap ETF (JHSC) a Strong ETF Right Now? (Zacks)
Apr-03-25 06:15AM	The Smartest Biotech Stocks to Buy With $50 (Motley Fool)
Apr-02-25 03:00PM	Biotech Stock Roundup: CORT Up on Study Data, Updates From AXSM, BMY, EXEL & More (Zacks)
09:48AM	Is Exelixis, Inc. (EXEL) The Most Profitable Biotech Stock To Buy Right Now? (Insider Monkey)
Mar-31-25 07:05PM	Orchestra BioMed Holdings, Inc. (OBIO) Reports Q4 Loss, Lags Revenue Estimates (Zacks)
Mar-30-25 03:50AM	abrdn Life Sciences Investors Q4 2024 Commentary (Seeking Alpha)
02:50AM	abrdn Healthcare Investors Q4 2024 Commentary (Seeking Alpha)
Mar-27-25 03:00PM	FDA Expands Exelixis Cabometyx Label for Neuroendocrine Tumors (Zacks)
11:05AM	Exelixis cabozantinib approval certainly positive, says Citi (TipRanks)
07:07AM	US FDA approves Exelixis' Cabometyx for advanced neuroendocrine tumours (Pharmaceutical Business Review)
Mar-26-25 05:20PM	Exelixis to present positive preclinical data across pipeline portfolio at AACR (TipRanks)
03:00PM	Exelixis Stock Rises 13.3% Year to Date: Buy, Sell or Hold? (Zacks)
09:45AM	Here's Why Exelixis (EXEL) is a Strong Growth Stock (Zacks)
09:15AM	Exelixis Announces U.S. FDA Approval of CABOMETYX (cabozantinib) for Patients with Previously Treated Advanced Neuroendocrine Tumors (Business Wire)
Mar-25-25 05:15PM	Exelixis to Present Positive Preclinical Data Across Its Pipeline Portfolio for Advanced Cancers at AACR 2025 (Business Wire)
Mar-24-25 10:57AM	Biotech Leader Exelixis Eyes Buy Point In Monday's Stock Market Rally (Investor's Business Daily)
Mar-21-25 11:30AM	Exact Sciences (EXAS) Down 10.6% Since Last Earnings Report: Can It Rebound? (Zacks)
Mar-20-25 12:30PM	Still Feeling Bearish? Best Defensive Stocks To Buy Now (SeekingAlpha)
11:20AM	Defensive Stocks For Unpredictable Trump Policy (SeekingAlpha)
09:40AM	Are You a Value Investor? This 1 Stock Could Be the Perfect Pick (Zacks)
Mar-19-25 07:09AM	Exelixis Growth Continues with Big Money Boosts (FX Empire)
Mar-18-25 05:30AM	Exelixis, Inc. (EXEL): Among the Best Biotech Stocks to Buy According to Billionaires (Insider Monkey)
Mar-13-25 11:30AM	Exelixis (EXEL) Up 13.4% Since Last Earnings Report: Can It Continue? (Zacks)
Mar-08-25 07:33AM	Why the Global Cancer Market Could Surpass $900 Billion--And the Stocks Leading the Charge (PR Newswire)
Mar-01-25 02:38PM	Is Exelixis, Inc. (EXEL) The Best Immunology Stock To Buy Now? (Insider Monkey)
Feb-28-25 04:33AM	Exelixis focuses on future growth despite COSMIC-313 trial challenges (Pharmaceutical Technology)
Feb-25-25 04:05PM	Exelixis to Webcast Fireside Chats at Upcoming Investor Conferences in March (Business Wire)
03:11PM	Analysts Give The Green Light To Two Stocks With Brighter Outlook Than Even Nvidia (Investor's Business Daily)
Feb-23-25 01:16PM	Exelixis, Inc. (EXEL): Among Renaissance Technologies Portfolios Top Stock Picks (Insider Monkey)
Feb-21-25 06:31PM	Why Exelixis Stock Trounced the Market on Thursday (Motley Fool) +5.02%
01:30PM	Why Is Cancer-Focused Exelixis Stock Trading Higher On Friday? (Benzinga)
Feb-20-25 05:05PM	Exelixis Announces a Newly Authorized $500 Million Stock Repurchase Program (Business Wire)
12:45PM	Is Exelixis (EXEL) a Solid Growth Stock? 3 Reasons to Think "Yes" (Zacks)
Feb-17-25 09:15AM	International Markets and Exelixis (EXEL): A Deep Dive for Investors (Zacks)
08:19AM	Five-year results see Exelixis RCC therapy extending overall survival (Clinical Trials Arena)
Feb-15-25 11:10AM	Exelixis Announces Final Five-Year Follow-up Results from CheckMate -9ER Trial Evaluating CABOMETYX (cabozantinib) in Combination with Opdivo (nivolumab) in Patients with Advanced Kidney Cancer at ASCO GU 2025 (Business Wire)
Feb-14-25 09:40AM	Exelixis (EXEL) is a Top-Ranked Value Stock: Should You Buy? (Zacks)
Feb-13-25 04:05PM	Exelixis to Participate in the Citi 2025 Virtual Oncology Leadership Summit (Business Wire) +5.15%
Feb-12-25 02:13AM	Exelixis Inc (EXEL) Q4 2024 Earnings Call Highlights: Strong Revenue Growth and Strategic ... (GuruFocus.com)
Feb-11-25 10:15PM	Exelixis (EXEL) Q4 2024 Earnings Call Transcript (Motley Fool)
06:00PM	Exelixis (EXEL) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates (Zacks)
05:25PM	Exelixis (EXEL) Q4 Earnings and Revenues Top Estimates (Zacks)
04:22PM	Exelixis: Q4 Earnings Snapshot (Associated Press Finance)
04:05PM	Exelixis Announces Fourth Quarter and Fiscal Year 2024 Financial Results and Provides Corporate Update (Business Wire)
Feb-10-25 09:00AM	2 Stocks to Buy With Less Than $40 (Motley Fool)
Feb-07-25 05:00AM	The 10 best stocks of the last decade (Quartz)
Feb-06-25 09:15AM	Curious about Exelixis (EXEL) Q4 Performance? Explore Wall Street Estimates for Key Metrics (Zacks)
Jan-29-25 09:40AM	Here's Why Exelixis (EXEL) is a Strong Value Stock (Zacks)
Jan-28-25 04:05PM	Exelixis to Release Fourth Quarter and Full Year 2024 Financial Results on Tuesday, February 11, 2025 (Business Wire)

Exelixis, Inc. operates as an oncology company, which focuses on discovering, developing, and commercialization of new medicines for difficult-to-treat cancers. Its products include cabometyx, cometriq, and cotellic. The company was founded by Stelios Papadopoulos on November 15, 1994, and is headquartered in Alameda, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Haley Patrick J.	EVP, Commercial	May 20 '25	Sale	44.06	34,387	1,515,091	412,072	May 22 07:25 PM
Heyman Tomas J.	Director	May 21 '25	Sale	44.29	4,544	201,254	32,470	May 22 07:25 PM
Heyman Tomas J.	Director	May 21 '25	Proposed Sale	44.29	4,544	201,259		May 21 04:08 PM
PATRICK JOSEPH HALEY	Officer	May 20 '25	Proposed Sale	44.06	34,387	1,514,998		May 20 05:23 PM
POSTE GEORGE	Director	May 16 '25	Option Exercise	19.77	20,634	407,934	189,654	May 16 08:58 PM
POSTE GEORGE	Director	May 16 '25	Sale	45.99	20,634	948,958	169,020	May 16 08:58 PM
Senner Christopher J.	EVP and CFO	May 16 '25	Option Exercise	18.80	100,000	1,880,000	1,067,842	May 16 08:58 PM
Senner Christopher J.	EVP and CFO	May 16 '25	Sale	46.00	100,000	4,600,000	967,842	May 16 08:58 PM
PAPADOPOULOS STELIOS	Director	May 15 '25	Option Exercise	20.09	36,508	733,351	1,300,050	May 16 08:57 PM
PAPADOPOULOS STELIOS	Director	May 15 '25	Sale	44.35	36,508	1,619,130	1,279,416	May 16 08:57 PM
MORRISSEY MICHAEL	President and CEO	May 14 '25	Option Exercise	18.80	308,365	5,797,262	1,931,374	May 16 08:57 PM
Hessekiel Jeffrey	EVP & General Counsel	May 15 '25	Sale	46.18	25,000	1,154,500	693,396	May 16 08:57 PM
Haley Patrick J.	EVP, Commercial	May 15 '25	Option Exercise	18.80	116,383	2,188,000	562,842	May 16 08:57 PM
Haley Patrick J.	EVP, Commercial	May 15 '25	Sale	47.96	126,383	6,061,703	446,459	May 16 08:57 PM
Haley Patrick J.	EVP, Commercial	May 14 '25	Sale	42.68	10,000	426,800	491,164	May 16 08:57 PM
Peterson Amy C.	EVP Prod Dev & Med Aff & CMO	May 16 '25	Option Exercise	21.75	40,000	870,000	538,169	May 16 08:57 PM
Peterson Amy C.	EVP Prod Dev & Med Aff & CMO	May 16 '25	Sale	45.47	72,776	3,309,125	465,393	May 16 08:57 PM
AMY PETERSON	Officer	May 16 '25	Proposed Sale	46.26	72,776	3,366,618		May 16 04:11 PM
CHRISTOPHER J SENNER	Officer	May 16 '25	Proposed Sale	46.00	100,000	4,600,000		May 16 04:09 PM
GEORGE POSTE	Director	May 16 '25	Proposed Sale	45.99	20,634	948,958		May 16 04:09 PM
STELIOS PAPADOPOULOS	Director	May 15 '25	Proposed Sale	44.35	36,508	1,619,130		May 15 06:00 PM
PATRICK JOSEPH HALEY	Officer	May 15 '25	Proposed Sale	48.05	116,383	5,592,739		May 15 05:09 PM
JEFFREY J HESSEKIEL	Officer	May 15 '25	Proposed Sale	46.18	25,000	1,154,610		May 15 04:29 PM
PATRICK JOSEPH HALEY	Officer	May 15 '25	Proposed Sale	46.95	10,000	469,500		May 15 04:05 PM
PATRICK JOSEPH HALEY	Officer	May 14 '25	Proposed Sale	42.68	10,000	426,800		May 14 04:22 PM
Aftab Dana	CSO/EVP Disc & Trans Research	May 01 '25	Sale	39.00	1,508	58,812	693,181	May 05 07:12 PM
DANA T AFTAB	Officer	May 01 '25	Proposed Sale	39.00	1,508	58,812		May 01 04:02 PM
Haley Patrick J.	EVP, Commercial	Mar 03 '25	Sale	38.80	10,000	388,000	341,028	Mar 05 08:47 PM
PATRICK JOSEPH HALEY	Officer	Mar 03 '25	Proposed Sale	38.80	10,000	388,000		Mar 03 04:18 PM
Smith Julie	Director	Feb 27 '25	Option Exercise	20.19	54,514	1,100,494	65,292	Feb 28 08:35 PM
Smith Julie	Director	Feb 28 '25	Option Exercise	19.77	19,294	381,442	30,072	Feb 28 08:35 PM
Smith Julie	Director	Feb 27 '25	Sale	38.13	54,514	2,078,619	10,778	Feb 28 08:35 PM
Smith Julie	Director	Feb 28 '25	Sale	37.62	19,294	725,840	10,778	Feb 28 08:35 PM
WYSZOMIERSKI JACK L	Director	Feb 28 '25	Option Exercise	20.50	15,874	325,417	365,373	Feb 28 08:34 PM
WYSZOMIERSKI JACK L	Director	Feb 28 '25	Sale	37.80	8,768	331,430	356,605	Feb 28 08:34 PM
JACK L WYSZOMIERSKI	Director	Feb 28 '25	Proposed Sale	37.80	8,768	331,394		Feb 28 04:05 PM
Smith Julie	Director	Feb 27 '25	Proposed Sale	37.13	73,808	2,740,491		Feb 27 05:12 PM
Haley Patrick J.	EVP, Commercial	Feb 24 '25	Sale	36.98	52,636	1,946,479	303,310	Feb 26 08:01 PM
Oliver Bob	Director	Feb 25 '25	Option Exercise	19.28	15,147	292,034	52,161	Feb 26 08:00 PM
Oliver Bob	Director	Feb 25 '25	Sale	37.25	18,647	694,601	33,514	Feb 26 08:00 PM
Aftab Dana	CSO/EVP Disc & Trans Research	Feb 24 '25	Sale	36.75	26,987	991,772	511,908	Feb 26 08:00 PM
Senner Christopher J.	EVP and CFO	Feb 24 '25	Option Exercise	18.80	29,314	551,103	808,921	Feb 26 08:00 PM
Senner Christopher J.	EVP and CFO	Feb 24 '25	Sale	36.14	29,314	1,059,408	779,607	Feb 26 08:00 PM
Oliver Bob	Director	Feb 25 '25	Proposed Sale	37.25	18,647	694,601		Feb 25 05:05 PM
Haley Patrick J.	Officer	Feb 24 '25	Proposed Sale	36.84	52,636	1,939,213		Feb 24 06:02 PM
Aftab Dana	Officer	Feb 24 '25	Proposed Sale	36.75	26,987	991,772		Feb 24 05:55 PM
Senner Christopher J.	Officer	Feb 24 '25	Proposed Sale	36.14	29,314	1,059,370		Feb 24 03:34 PM
Beckerle Mary C	Director	Feb 14 '25	Option Exercise	23.24	8,354	194,147	42,616	Feb 19 08:32 PM
Beckerle Mary C	Director	Feb 14 '25	Sale	34.88	12,210	425,878	30,406	Feb 19 08:32 PM
POSTE GEORGE	Director	Feb 14 '25	Option Exercise	20.50	15,874	325,417	184,894	Feb 19 08:32 PM
POSTE GEORGE	Director	Feb 14 '25	Sale	34.74	15,874	551,463	169,020	Feb 19 08:32 PM
Freire Maria C	Director	Feb 14 '25	Option Exercise	21.52	44,114	949,521	135,121	Feb 19 08:31 PM
Freire Maria C	Director	Feb 14 '25	Sale	34.94	44,114	1,541,343	91,007	Feb 19 08:31 PM
Eckhardt Sue Gail	Director	Feb 14 '25	Option Exercise	23.24	7,712	179,227	41,974	Feb 19 08:31 PM
Eckhardt Sue Gail	Director	Feb 14 '25	Sale	35.02	11,568	405,111	30,406	Feb 19 08:31 PM
Freire Maria C	Director	Feb 14 '25	Proposed Sale	34.94	44,114	1,541,207		Feb 14 05:59 PM
Beckerle Mary C	Director	Feb 14 '25	Proposed Sale	34.88	12,210	425,865		Feb 14 05:40 PM
POSTE GEORGE	Director	Feb 14 '25	Proposed Sale	34.74	15,874	551,431		Feb 14 05:36 PM
Eckhardt Sue Gail	Director	Feb 14 '25	Proposed Sale	34.37	11,568	397,592		Feb 14 04:20 PM
Hessekiel Jeffrey	EVP & General Counsel	Nov 27 '24	Option Exercise	18.80	129,314	2,431,103	644,967	Dec 02 08:29 PM
Hessekiel Jeffrey	EVP & General Counsel	Nov 29 '24	Sale	36.67	60,000	2,200,200	486,059	Dec 02 08:29 PM
JEFFREY HESSEKIEL	Officer	Nov 29 '24	Proposed Sale	36.67	60,000	2,200,230		Nov 29 01:12 PM
Haley Patrick J.	EVP, Commercial	Nov 22 '24	Sale	35.27	10,000	352,700	278,665	Nov 26 07:05 PM
PATRICK JOSEPH HALEY	Officer	Nov 22 '24	Proposed Sale	35.27	10,000	352,700		Nov 22 04:01 PM
Haley Patrick J.	EVP, Commercial	Nov 18 '24	Sale	34.36	41,588	1,428,822	288,665	Nov 19 08:03 PM
Haley Patrick J.	Officer	Nov 18 '24	Proposed Sale	34.41	19,381	666,974		Nov 18 06:50 PM
PATRICK JOSEPH HALEY	Officer	Nov 18 '24	Proposed Sale	34.31	22,207	761,884		Nov 18 04:10 PM
Aftab Dana	CSO/EVP Disc & Trans Research	Nov 05 '24	Option Exercise	18.80	96,986	1,823,337	595,931	Nov 07 07:44 PM
Aftab Dana	CSO/EVP Disc & Trans Research	Nov 05 '24	Sale	35.00	96,986	3,394,510	498,945	Nov 07 07:44 PM
Hessekiel Jeffrey	EVP & General Counsel	Nov 01 '24	Sale	34.13	50,000	1,706,500	530,325	Nov 05 07:05 PM
POSTE GEORGE	Director	Nov 01 '24	Sale	34.00	30,000	1,020,000	169,020	Nov 05 07:04 PM
DANA T AFTAB	Officer	Nov 05 '24	Proposed Sale	35.00	96,986	3,394,510		Nov 05 04:23 PM
Aftab Dana	CSO/EVP Disc & Trans Research	Oct 30 '24	Sale	31.40	1,162	36,487	498,945	Nov 01 06:43 PM
POSTE GEORGE	Director	Nov 01 '24	Proposed Sale	34.00	30,000	1,020,112		Nov 01 04:54 PM
JEFFREY J HESSEKIEL	Officer	Nov 01 '24	Proposed Sale	33.20	25,000	830,000		Nov 01 04:47 PM
Hessekiel Jeffrey	EVP & General Counsel	Oct 28 '24	Sale	28.39	25,000	709,750	580,325	Oct 30 06:04 PM
DANA T AFTAB	Officer	Oct 30 '24	Proposed Sale	31.40	1,162	36,487		Oct 30 04:10 PM
Haley Patrick J.	EVP, Commercial	Oct 02 '24	Option Exercise	24.41	100,000	2,441,000	441,036	Oct 03 09:22 PM
MORRISSEY MICHAEL	President and CEO	Oct 01 '24	Option Exercise	24.41	480,000	11,716,800	1,444,384	Oct 03 09:22 PM
Hessekiel Jeffrey	EVP & General Counsel	Sep 23 '24	Sale	26.38	25,000	659,500	605,325	Sep 25 07:32 PM
JEFFREY J HESSEKIEL	Officer	Sep 23 '24	Proposed Sale	26.42	75,000	1,981,500		Sep 23 04:24 PM
Hessekiel Jeffrey	EVP, General Counsel & Sec	Aug 26 '24	Option Exercise	24.41	20,000	488,200	650,325	Aug 28 07:07 PM
Hessekiel Jeffrey	EVP, General Counsel & Sec	Aug 26 '24	Sale	25.79	20,000	515,800	630,325	Aug 28 07:07 PM
Freire Maria C	Director	Aug 14 '24	Sale	26.56	8,250	219,120	91,007	Aug 16 07:35 PM
Aftab Dana	CSO/EVP Disc & Trans Research	Aug 12 '24	Sale	27.06	20,883	565,094	500,107	Aug 14 07:12 PM
MARIA C FREIRE	Director	Aug 14 '24	Proposed Sale	26.56	8,250	219,122		Aug 14 05:01 PM
POSTE GEORGE	Director	Aug 08 '24	Sale	26.89	33,725	906,865	199,020	Aug 12 07:22 PM
Aftab Dana	CSO/EVP Disc & Trans Research	Aug 07 '24	Option Exercise	24.41	95,000	2,318,950	615,990	Aug 09 07:32 PM
Aftab Dana	CSO/EVP Disc & Trans Research	Aug 07 '24	Sale	25.00	95,000	2,375,000	520,990	Aug 09 07:32 PM
Haley Patrick J.	EVP, Commercial	Aug 07 '24	Sale	25.50	14,000	357,000	341,036	Aug 09 07:32 PM
Hessekiel Jeffrey	EVP, General Counsel & Sec	Aug 07 '24	Option Exercise	24.41	80,000	1,952,800	710,325	Aug 09 07:32 PM
Hessekiel Jeffrey	EVP, General Counsel & Sec	Aug 07 '24	Sale	25.97	80,000	2,077,600	630,325	Aug 09 07:32 PM
Senner Christopher J.	EVP and CFO	Aug 09 '24	Option Exercise	24.41	125,000	3,051,250	846,680	Aug 09 07:31 PM
Senner Christopher J.	EVP and CFO	Aug 09 '24	Sale	27.19	125,000	3,398,750	721,680	Aug 09 07:31 PM
Senner Christopher J.	Officer	Aug 09 '24	Proposed Sale	27.17	125,000	3,396,250		Aug 09 05:20 PM
Aftab Dana	Officer	Aug 09 '24	Proposed Sale	27.25	20,883	569,062		Aug 09 05:18 PM
POSTE GEORGE	Director	Aug 08 '24	Proposed Sale	26.89	33,725	906,746		Aug 08 05:42 PM
DANA T AFTAB	Officer	Aug 07 '24	Proposed Sale	25.00	95,000	2,375,000		Aug 07 04:17 PM
JEFFREY J HESSEKIEL	Officer	Aug 07 '24	Proposed Sale	23.45	100,000	2,345,000		Aug 07 04:13 PM
PATRICK JOSEPH HALEY	Officer	Aug 07 '24	Proposed Sale	25.50	14,000	357,000		Aug 07 04:11 PM

Open in Screener

AKRO

Akero Therapeutics Inc

May 23 • 02:08PM ET

45.99

Dollar change -2.98
Percentage change -6.09	%

Healthcare • Biotechnology • USA • NASD

AKRO Akero Therapeutics Inc daily Stock Chart

Peers: MDGL ARWR HALO GNFT ALLK VKTX NBIX ENTA GALT SLDB

| Held by: VTI IWM VXF XBI IWN IBB VTWO SCHA SURI VHT

Index	RUT	P/E	-	EPS (ttm)	-3.75	Insider Own	10.67%	Shs Outstand	79.67M	Perf Week	18.32%
Market Cap	3.67B	Forward P/E	-	EPS next Y	-4.41	Insider Trans	-1.60%	Shs Float	71.21M	Perf Month	12.20%
Income	-269.44M	PEG	-	EPS next Q	-0.93	Inst Own	102.01%	Short Float	9.53%	Perf Quarter	-7.28%
Sales	0.00M	P/S	-	EPS this Y	-3.81%	Inst Trans	2.40%	Short Ratio	5.30	Perf Half Y	48.21%
Book/sh	13.60	P/B	3.38	EPS next Y	-13.30%	ROA	-26.06%	Short Interest	6.78M	Perf Year	127.22%
Cash/sh	8.61	P/C	5.34	EPS next 5Y	-8.83%	ROE	-27.92%	52W Range	17.86 - 58.40	Perf YTD	65.31%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-5.28%	ROI	-24.21%	52W High	-21.25%	Beta	-0.17
Dividend TTM	-	Quick Ratio	16.80	Sales past 5Y	0.00%	Gross Margin	-	52W Low	157.50%	ATR (14)	3.07
Dividend Ex-Date	-	Current Ratio	16.80	EPS Y/Y TTM	-17.04%	Oper. Margin	-	RSI (14)	57.33	Volatility	10.99% 6.12%
Employees	63	Debt/Eq	0.03	Sales Y/Y TTM	-	Profit Margin	-	Recom	1.00	Target Price	73.83
Option/Short	Yes / Yes	LT Debt/Eq	0.03	EPS Q/Q	0.02%	Payout	-	Rel Volume	0.98	Prev Close	48.97
Sales Surprise	-	EPS Surprise	6.17%	Sales Q/Q	-	Earnings	May 12 BMO	Avg Volume	1.28M	Price	45.99
SMA20	6.92%	SMA50	11.01%	SMA200	30.83%	Trades		Volume	910,544	Change	-6.09%

Date	Action	Analyst	Rating Change	Price Target Change
Jan-30-25	Upgrade	BofA Securities	Neutral → Buy	$35 → $63
Jan-27-25	Reiterated	H.C. Wainwright	Buy	$50 → $72
Nov-18-24	Initiated	Citigroup	Buy	$65
Apr-22-24	Resumed	BofA Securities	Neutral	$30
Sep-19-23	Initiated	Cantor Fitzgerald	Overweight	$69
Aug-28-23	Initiated	UBS	Buy	$83
Jan-27-23	Upgrade	Morgan Stanley	Equal-Weight → Overweight	$40 → $65
Sep-14-22	Upgrade	Evercore ISI	In-line → Outperform	$10 → $50
Oct-19-21	Downgrade	Morgan Stanley	Overweight → Equal-Weight	$27
Sep-10-21	Initiated	BofA Securities	Buy	$40
Feb-26-21	Initiated	Guggenheim	Buy	$54
Sep-10-20	Initiated	Morgan Stanley	Overweight	$70
Jul-20-20	Reiterated	H.C. Wainwright	Buy	$45 → $62
Jul-07-20	Initiated	Chardan Capital Markets	Buy	$79
Jul-01-20	Reiterated	H.C. Wainwright	Buy	$33 → $45
Mar-02-20	Initiated	H.C. Wainwright	Buy	$33
Feb-10-20	Initiated	Canaccord Genuity	Buy	$36
Jul-15-19	Initiated	ROTH Capital	Buy	$34
Jul-15-19	Initiated	JP Morgan	Overweight	$28
Jul-15-19	Initiated	Jefferies	Buy	$28

Show Previous Ratings

May-20-25 11:51PM	Why Akero Therapeutics, Inc. (AKRO) Skyrocketed Today (Insider Monkey) +24.72%
May-13-25 08:10AM	Best Biotech Stocks to Buy in 2025 (MarketBeat)
May-12-25 07:00AM	Akero Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update (GlobeNewswire)
May-11-25 05:21PM	Why Akero Therapeutics (AKRO) Is Among the Best Performing Healthcare Stocks to Buy Now (Insider Monkey)
May-10-25 10:00AM	Akero Therapeutics and HistoIndex Present New Analyses of Phase 2b HARMONY Trial in Oral and Poster Presentations at the EASL Congress 2025 (GlobeNewswire)
07:41AM	Loading…
May-09-25 07:41AM	Akero Therapeutics Presents Week 96 Results from Phase 2b SYMMETRY Clinical Trial of Efruxifermin in Patients with Compensated Cirrhosis Caused by MASH Showing Fibrosis Improvement without Worsening of MASH at the EASL Congress 2025 (GlobeNewswire) -5.99%
07:11AM	Akero Therapeutics Announces Publication of Phase 2b SYMMETRY Trial in the New England Journal of Medicine (GlobeNewswire)
May-07-25 04:05PM	Akero Therapeutics to Present at the BofA Securities 2025 Healthcare Conference (GlobeNewswire)
Apr-30-25 07:00AM	Akero Therapeutics Announces Upcoming Poster and Oral Presentations at the EASL Congress 2025 (GlobeNewswire) +5.97%
Apr-18-25 04:46AM	89bio: A Buy With Strong Market Opportunity In MASH And SHTG (Seeking Alpha)
Apr-17-25 10:28AM	89bio: Primary Asset Targeting 2 Potential Indications And Is In Late-Stage Development (Seeking Alpha)
Apr-06-25 01:47PM	Akero Therapeutics: Cirrhosis Reversal Data Derisks The Stock (Seeking Alpha)
Mar-24-25 09:13AM	Notice to Long-Term Shareholders of Akero Therapeutics, Inc. (Nasdaq: AKRO); Driven Brands Holdings, Inc. (Nasdaq: DRVN); Integra Lifesciences Holdings Corporation (Nasdaq: IART); and Kyverna Therapeutics, Inc. (Nasdaq: KYTX): Grabar Law Office is Investigating Claims on Your Behalf (GlobeNewswire)
Mar-02-25 09:34AM	Why Akero Therapeutics, Inc. (AKRO) is Skyrocketing So Far in 2025 (Insider Monkey)
Feb-28-25 07:00AM	Akero Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update (GlobeNewswire)
01:23PM	Loading…
Feb-27-25 01:23PM	Is Akero Therapeutics Inc. (AKRO) the Best Performing Mid Cap Stock to Buy According to Analysts? (Insider Monkey)
Feb-23-25 03:18PM	Akero Therapeutics, Inc. (AKRO): the Best Performing Pharma Stock So Far in 2025 (Insider Monkey)
Feb-20-25 08:42AM	Grabar Law Office is Investigating Claims on Behalf of Long-Term Shareholders of Akero Therapeutics, Inc. (NASDAQ: AKRO); Crocs, Inc. (NASDAQ: CROX); Extreme Networks, Inc. (NASDAQ: EXTR); and Domino's Pizza Corp. (NASDAQ: DPZ) (GlobeNewswire)
Feb-19-25 02:45PM	Akero Therapeutics, Inc. (AKRO): the Best Performing Healthcare Stock So Far in 2025 (Insider Monkey)
Feb-03-25 07:25PM	Why Akero Therapeutics Inc (AKRO) Is Skyrocketing So Far In 2025 (Insider Monkey)
12:28PM	Akero Therapeutics Inc. (AKRO): Among The Stocks That Started The Year On A High (Insider Monkey)
Feb-02-25 06:21PM	This Stock Just Doubled in 1 Day -- Is It Still a Buy? (Motley Fool)
04:35PM	Why Akero Therapeutics (AKRO) Is Among the Best Booming Stocks to Invest in Now? (Insider Monkey)
Jan-30-25 04:05PM	Akero Therapeutics Announces Closing of Upsized Public Offering of Common Stock and Pre-Funded Warrants and Full Exercise of Underwriters' Option to Purchase Additional Shares (GlobeNewswire)
Jan-29-25 05:39AM	BioAge drops obesity drug; Akero, 89bio cash in on MASH data (BioPharma Dive)
Jan-28-25 09:30PM	Akero Therapeutics Announces Pricing of Upsized Public Offering of Common Stock and Pre-Funded Warrants (GlobeNewswire)
11:14AM	Akeros cirrhosis treatment shows promise in Phase IIb study (Clinical Trials Arena)
08:40AM	Why Akero Therapeutics Inc. (AKRO) Surged on Monday (Insider Monkey)
Jan-27-25 04:24PM	Akero Therapeutics Stock Nearly Doubles Pulling 89bio Higher On Positive MASH Study (Investor's Business Daily) +97.52%
04:01PM	Akero Therapeutics Announces Proposed Public Offering of Common Stock (GlobeNewswire)
12:13PM	Loading…
12:13PM	Akero's Stock Skyrockets 112% After Game-Changing Liver Drug Data (GuruFocus.com)
11:27AM	Akero Therapeutics Stock Doubles on Liver Disease Drug Trial Results (Investopedia)
11:10AM	Akero Therapeutics Shares Surge 106% as Phase 2b Study Shows Significant Cirrhosis Reversal (GuruFocus.com)
10:57AM	Akero Therapeutics Stock Doubles on Liver Data (Barrons.com)
09:01AM	Liver Disease-Focused Akero Therapeutics Stock Soars Over 100% On Monday - Here's Why (Benzinga)
06:30AM	Akero Therapeutics Reports Preliminary Topline Results Showing Statistically Significant Reversal of Compensated Cirrhosis (F4) Due to MASH by Both Completer and ITT Analyses at Week 96 in Phase 2b SYMMETRY Study (GlobeNewswire)
Jan-24-25 04:05PM	Akero Therapeutics to Present Preliminary Topline Week 96 Results from Phase 2b SYMMETRY Study Investigating Efruxifermin in Patients with Compensated Cirrhosis (F4) Due to MASH (GlobeNewswire)
Jan-13-25 07:00AM	Akero Therapeutics Completes Enrollment of the Double-Blind Portion of the Phase 3 SYNCHRONY Real-World Study Evaluating Efruxifermin (EFX) in Patients with Non-Invasively Diagnosed MASH or MASLD (GlobeNewswire) -8.90%
Jan-09-25 12:18PM	Notice to Akero Therapeutics, Inc. (AKRO) Shareholders: Grabar Law Office Is Investigating Claims on Your Behalf (Newsfile)
Jan-07-25 07:00AM	Akero Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-04-24 12:59PM	Why Is Akero Therapeutics, Inc. (AKRO) Among the Best Small-Cap Biotech Stocks With Massive Potential According to Hedge Funds? (Insider Monkey)
Nov-26-24 07:00AM	Akero Therapeutics to Present at the 7th Annual Evercore ISI HealthCONx Conference (GlobeNewswire)
Nov-15-24 11:00AM	Akero Therapeutics to Showcase New Analyses of Phase 2b HARMONY Study in Presentations at 75th Annual AASLD The Liver Meeting 2024 (GlobeNewswire) -5.61%
Nov-13-24 04:05PM	Akero Therapeutics to Present at the Jefferies London Healthcare Conference (GlobeNewswire)
Nov-12-24 11:00PM	Akero Therapeutics Advances in MASH Treatment Trials (TipRanks)
Nov-08-24 07:00AM	Akero Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update (GlobeNewswire)
Nov-02-24 12:00PM	Madrigal, 89Bio jump after Novos semaglutide shows promise in MASH (TipRanks)
Nov-01-24 04:06AM	Notice to Akero Therapeutics, Inc. (AKRO) Shareholders: Grabar Law Office Is Investigating Claims of Misconduct on Your Behalf (Newsfile)
Oct-30-24 06:00AM	Axonis Therapeutics Announces $115 Million Series A Financing (PR Newswire)
Oct-21-24 07:00AM	Akero Therapeutics to Present Data Reinforcing the Efficacy of Efruxifermin at the 75th Annual AASLD The Liver Meeting 2024 (GlobeNewswire)
Oct-17-24 03:02PM	State Street Corp's Strategic Reduction in Akero Therapeutics Inc Shares (GuruFocus.com)
Oct-16-24 08:44AM	Akero Therapeutics (AKRO): Leading the Charge in MASH Treatment with Efruxifermin (Insider Monkey)
Oct-15-24 06:10PM	Akero Therapeutics, Inc. (AKRO): A Visionary Small-Cap Stock Pick by Hedge Funds (Insider Monkey)
Sep-30-24 07:00AM	Akero Therapeutics to Present at the H.C. Wainwright 8th Annual MASH Virtual Conference (GlobeNewswire)
Sep-12-24 01:12AM	Wellington Management Group LLP's Strategic Acquisition in Akero Therapeutics Inc (GuruFocus.com)
Sep-09-24 07:00AM	Akero Therapeutics Announces First Patient Dosed in Phase 3 SYNCHRONY Outcomes Study of Efruxifermin in Patients with Compensated Cirrhosis Due to MASH (GlobeNewswire)
Sep-05-24 12:02AM	Akero Therapeutics, Inc. (AKRO): This Small-Cap Healthcare Stock Is A Good Buy Right Now (Insider Monkey)
Sep-02-24 05:22PM	10 Best Small-Cap Healthcare Stocks To Buy Now (Insider Monkey)
Aug-28-24 04:05PM	Akero Therapeutics to Present at the Morgan Stanley 22nd Annual Global Healthcare Conference (GlobeNewswire)
Aug-09-24 02:53PM	AKRO Stock Earnings: Akero Therapeutics Beats EPS for Q2 2024 (InvestorPlace)
07:00AM	Akero Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update (GlobeNewswire)
Jul-16-24 12:00PM	Akero Therapeutics (AKRO) Moves to Buy: Rationale Behind the Upgrade (Zacks)
Jun-28-24 10:40AM	Lowey Dannenberg, P.C. is Investigating Akero Therapeutics, Inc. ( Akero ) (NASDAQ: AKRO) for Potential Violations of the Federal Securities Laws and Encourages Investors with Losses to Contact the Firm (GlobeNewswire)
Jun-24-24 01:04PM	Lowey Dannenberg, P.C. is Investigating Akero Therapeutics, Inc. ( Akero ) (NASDAQ: AKRO) for Potential Violations of the Federal Securities Laws and Encourages Investors with Losses to Contact the Firm (GlobeNewswire)
Jun-21-24 11:06AM	Lowey Dannenberg, P.C. is Investigating Akero Therapeutics, Inc. ( Akero ) (NASDAQ: AKRO) for Potential Violations of the Federal Securities Laws and Encourages Investors with Losses to Contact the Firm (GlobeNewswire) +6.52%
Jun-19-24 02:45PM	Lowey Dannenberg, P.C. is Investigating Akero Therapeutics, Inc. ( Akero ) (NASDAQ: AKRO) for Potential Violations of the Federal Securities Laws and Encourages Investors with Losses to Contact the Firm (GlobeNewswire)
Jun-17-24 10:23AM	Lowey Dannenberg, P.C. is Investigating Akero Therapeutics, Inc. ( Akero ) (NASDAQ: AKRO) for Potential Violations of the Federal Securities Laws and Encourages Investors with Losses to Contact the Firm (GlobeNewswire)
Jun-13-24 03:57PM	Lowey Dannenberg, P.C. is Investigating Akero Therapeutics, Inc. ( Akero ) (NASDAQ: AKRO) for Potential Violations of the Federal Securities Laws and Encourages Investors with Losses to Contact the Firm (GlobeNewswire)
09:00AM	The Lustgarten Foundation Appoints Two New Board Members (PR Newswire)
Jun-11-24 07:00AM	Akero Therapeutics Announces Initiation of Phase 3 SYNCHRONY Outcomes Trial of Efruxifermin in Patients with Compensated Cirrhosis (F4) Due to MASH (GlobeNewswire)
Jun-10-24 10:14AM	Lowey Dannenberg, P.C. is Investigating Akero Therapeutics, Inc. ( Akero ) (NASDAQ: AKRO) for Potential Violations of the Federal Securities Laws and Encourages Investors with Losses to Contact the Firm (GlobeNewswire)
Jun-08-24 08:15AM	Akero Therapeutics Presents Poster and Late-breaking Oral Presentation on EFX at the EASL Congress 2024 (GlobeNewswire)
Jun-06-24 10:39AM	Lowey Dannenberg, P.C. is Investigating Akero Therapeutics, Inc. ( Akero ) (NASDAQ: AKRO) for Potential Violations of the Federal Securities Laws and Encourages Investors with Losses to Contact the Firm (GlobeNewswire)
Jun-03-24 09:57AM	Lowey Dannenberg, P.C. is Investigating Akero Therapeutics, Inc. ( Akero ) (NASDAQ: AKRO) for Potential Violations of the Federal Securities Laws and Encourages Investors with Losses to Contact the Firm (GlobeNewswire)
May-30-24 09:16PM	Lowey Dannenberg, P.C. is Investigating Akero Therapeutics, Inc. ( Akero ) (NASDAQ: AKRO) for Potential Violations of the Federal Securities Laws and Encourages Investors with Losses to Contact the Firm (GlobeNewswire)
May-29-24 07:00AM	Akero Therapeutics to Present at the Jefferies Global Healthcare Conference (GlobeNewswire)
May-23-24 02:12PM	Lowey Dannenberg, P.C. is Investigating Akero Therapeutics, Inc. ( Akero ) (NASDAQ: AKRO) for Potential Violations of the Federal Securities Laws and Encourages Investors with Losses to Contact the Firm (GlobeNewswire) -7.76%
May-15-24 09:26AM	Evercore ISI Adjusts Price Target on Akero Therapeutics to $38 From $50, Maintains Outperform Rating (MT Newswires)
May-12-24 09:01PM	Akero Therapeutics Inc (AKRO) Q1 2024 Earnings: Misses Analyst Forecast Amid Continued ... (GuruFocus.com)
May-10-24 01:54PM	AKRO Stock Earnings: Akero Therapeutics Beats EPS for Q1 2024 (InvestorPlace) -5.53%
07:45AM	Akero Therapeutics' Q1 Net Loss Widens; Cash Expected to Fund Operations Into H2 2027 (MT Newswires)
07:00AM	Akero Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update (GlobeNewswire)
May-08-24 07:00AM	Akero Therapeutics to Present at the BofA Securities 2024 Health Care Conference (GlobeNewswire)
Apr-30-24 08:00AM	Akero Therapeutics Appoints Scott Gangloff as Chief Technology Officer (GlobeNewswire)
Apr-22-24 06:00AM	6 Stocks Positioned to Soar as Investors Focus on MASH (News Direct)
Mar-20-24 01:32PM	Billionaire Steve Cohen and Insiders Are Buying These 10 Stocks (Insider Monkey)
12:58PM	AKRO Investor Notice: Abraham, Fruchter & Twersky, LLP Investigating Claims on Behalf of Investors of Akero Therapeutics (NASDAQ:AKRO) (GlobeNewswire)
Mar-18-24 07:00AM	Ozempic Cant Do It AllA Potential New Blockbuster Is a Reminder of That (The Wall Street Journal)
Mar-08-24 04:02PM	Akero Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares (GlobeNewswire) -6.00%
Mar-07-24 04:01PM	Akero Therapeutics Announces Publication of Phase 2b SYMMETRY Cohort D Study in Clinical Gastroenterology and Hepatology (GlobeNewswire)
Mar-06-24 11:54PM	President and CEO Andrew Cheng Sells 75,000 Shares of Akero Therapeutics Inc (AKRO) (GuruFocus.com)
Mar-05-24 09:13PM	Akero Therapeutics Announces Pricing of Public Offering of Common Stock (GlobeNewswire)
02:12PM	Akero (AKRO) Up on Upbeat Week 96 Data From Liver Disease Study (Zacks)
Mar-04-24 04:21PM	Akero Therapeutics Announces Proposed Public Offering of Common Stock (GlobeNewswire) +11.72%
04:04PM	Why Akero Rocketed And Pulled Rival 89bio Higher On Results In Liver Disease Treatment (Investor's Business Daily)
12:30PM	Data Suggests Makers of Fatty Liver Treatments Wont Be Displaced by Obesity Drugs (The Wall Street Journal)
11:59AM	Akero Therapeutics Bats Back Challenge From Lilly in Emerging Liver-Drug Market (Barrons.com)
09:23AM	Akero Rockets 27%, Prodding Rival 89bio Higher, On Promising Liver Disease Treatment (Investor's Business Daily)
06:22AM	UPDATE 1-Akero's lead drug helps reduce scarring in fatty liver disease patients (Reuters)
06:09AM	Akero's lead drug helps improve scarring in fatty liver disease patients (Reuters)

Akero Therapeutics, Inc. is a clinical-stage company, which engages in the development of treatments for patients with serious metabolic diseases. The firm's lead product candidate, efruxifermin (EFX), is an analog of fibroblast growth factor 21, or FGF21, which is an endogenously expressed hormone that protects against cellular stress and regulates metabolism of lipids, carbohydrates, and proteins throughout the body. The company was founded by Jonathan Young and Timothy Rolph in January 2017 and is headquartered in South San Francisco, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
PATRICK D LAMY	Officer	May 22 '25	Proposed Sale	48.35	10,000	483,500		May 22 04:20 PM
Yale Catriona	Chief Development Officer	May 15 '25	Option Exercise	21.10	10,000	211,000	105,034	May 19 07:06 PM
Yale Catriona	Chief Development Officer	May 15 '25	Sale	39.30	10,000	392,978	95,034	May 19 07:06 PM
CATRIONA YALE	Officer	May 15 '25	Proposed Sale	37.88	30,000	1,136,400		May 15 04:27 PM
Cheng Andrew	President and CEO	May 12 '25	Sale	41.48	30,000	1,244,455	594,324	May 13 09:11 PM
Andrew Cheng	Officer	May 12 '25	Proposed Sale	39.85	120,000	4,782,000		May 12 06:47 PM
Lamy Patrick	Senior VP, Commercial Strategy	May 07 '25	Option Exercise	19.87	8,000	158,960	41,492	May 09 07:18 PM
Lamy Patrick	Senior VP, Commercial Strategy	May 07 '25	Sale	42.49	8,000	339,950	33,492	May 09 07:18 PM
Rolph Timothy	Chief Scientific Officer	May 06 '25	Option Exercise	21.10	12,500	263,750	182,221	May 08 07:34 PM
Rolph Timothy	Chief Scientific Officer	May 06 '25	Sale	43.43	12,500	542,864	169,721	May 08 07:34 PM
Timothy Rolph	Officer	May 06 '25	Proposed Sale	40.00	50,000	2,000,000		May 06 04:41 PM
Rolph Timothy	Chief Scientific Officer	Apr 24 '25	Option Exercise	21.10	6,250	131,875	175,971	Apr 28 06:22 PM
Rolph Timothy	Chief Scientific Officer	Apr 24 '25	Sale	41.03	6,250	256,438	169,721	Apr 28 06:22 PM
Yale Catriona	Chief Development Officer	Apr 15 '25	Option Exercise	21.10	9,073	191,440	104,107	Apr 16 06:00 PM
Yale Catriona	Chief Development Officer	Apr 15 '25	Sale	37.91	9,073	343,962	95,034	Apr 16 06:00 PM
Cheng Andrew	President and CEO	Apr 10 '25	Sale	35.23	30,000	1,056,780	624,324	Apr 11 06:00 PM
Rolph Timothy	Chief Scientific Officer	Apr 07 '25	Option Exercise	21.10	6,250	131,875	175,971	Apr 10 06:00 PM
Rolph Timothy	Chief Scientific Officer	Apr 07 '25	Sale	35.88	6,250	224,262	169,721	Apr 10 06:00 PM
PATRICK D LAMY	Officer	Apr 07 '25	Proposed Sale	36.73	8,000	293,840		Apr 07 04:24 PM
Graham G. Walmsley	Director	Mar 25 '25	Buy	44.75	91,309	4,085,804	1,091,309	Mar 27 07:42 PM
Graham G. Walmsley	Director	Mar 26 '25	Buy	43.01	58,691	2,524,417	1,150,000	Mar 27 07:42 PM
Graham G. Walmsley	Director	Mar 27 '25	Buy	43.55	50,000	2,177,700	1,200,000	Mar 27 07:42 PM
Yale Catriona	Chief Development Officer	Mar 17 '25	Option Exercise	21.10	10,000	211,000	105,034	Mar 18 05:30 PM
Yale Catriona	Chief Development Officer	Mar 17 '25	Sale	44.76	10,000	447,605	95,034	Mar 18 05:30 PM
Cheng Andrew	President and CEO	Mar 12 '25	Sale	44.88	1,738	78,001	654,324	Mar 14 09:18 PM
Young Jonathan	Chief Operating Officer	Mar 12 '25	Sale	44.88	607	27,242	200,540	Mar 14 08:33 PM
Yale Catriona	Chief Development Officer	Mar 12 '25	Sale	44.88	614	27,556	95,034	Mar 14 08:30 PM
White William Richard	Chief Financial Officer	Mar 12 '25	Sale	44.88	676	30,339	61,959	Mar 14 08:24 PM
Rolph Timothy	Chief Scientific Officer	Mar 12 '25	Sale	44.88	516	23,158	169,721	Mar 14 08:18 PM
Cheng Andrew	President and CEO	Mar 10 '25	Sale	41.77	30,000	1,253,069	656,062	Mar 12 06:00 PM
Rolph Timothy	Chief Scientific Officer	Mar 05 '25	Option Exercise	21.10	12,500	263,750	182,737	Mar 07 05:30 PM
Rolph Timothy	Chief Scientific Officer	Mar 05 '25	Sale	44.53	12,500	556,590	170,237	Mar 07 05:30 PM
Young Jonathan	Chief Operating Officer	Mar 04 '25	Sale	44.86	50,000	2,243,213	201,147	Mar 05 06:56 PM
Lamy Patrick	Senior VP, Commercial Strategy	Mar 03 '25	Option Exercise	19.87	1,000	19,870	34,492	Mar 05 06:55 PM
Lamy Patrick	Senior VP, Commercial Strategy	Mar 03 '25	Sale	48.09	1,000	48,090	33,492	Mar 05 06:55 PM
Yale Catriona	Chief Development Officer	Feb 18 '25	Option Exercise	21.10	10,000	211,000	105,648	Feb 21 05:31 PM
Yale Catriona	Chief Development Officer	Feb 18 '25	Sale	49.87	10,000	498,660	95,648	Feb 21 05:31 PM
Cheng Andrew	President and CEO	Feb 10 '25	Sale	52.73	30,000	1,581,994	686,062	Feb 11 09:30 PM
Graham G. Walmsley	Director	Jan 30 '25	Buy	48.00	200,000	9,600,000	1,000,000	Feb 07 07:54 PM
Rolph Timothy	Chief Scientific Officer	Feb 05 '25	Option Exercise	21.10	18,750	395,625	188,987	Feb 07 06:05 PM
Rolph Timothy	Chief Scientific Officer	Feb 05 '25	Sale	56.51	18,750	1,059,630	170,237	Feb 07 06:05 PM
Young Jonathan	Chief Operating Officer	Feb 03 '25	Sale	53.81	10,000	538,061	251,147	Feb 05 09:03 AM
Yale Catriona	Chief Development Officer	Jan 27 '25	Option Exercise	10.48	53,590	561,807	149,238	Jan 31 09:14 AM
Yale Catriona	Chief Development Officer	Jan 27 '25	Sale	56.25	53,590	3,014,216	95,648	Jan 31 09:14 AM
Yale Catriona	Chief Development Officer	Jan 27 '25	Option Exercise	21.10	49,074	1,035,461	144,722	Jan 31 09:14 AM
Yale Catriona	Chief Development Officer	Jan 27 '25	Sale	55.72	49,074	2,734,212	95,648	Jan 31 09:14 AM
Rolph Timothy	Chief Scientific Officer	Jan 27 '25	Option Exercise	20.51	31,250	640,942	201,487	Jan 29 08:43 PM
Rolph Timothy	Chief Scientific Officer	Jan 27 '25	Sale	55.77	31,250	1,742,958	170,237	Jan 29 08:43 PM
Lamy Patrick	Senior VP, Commercial Strategy	Jan 27 '25	Option Exercise	19.87	4,000	79,480	38,492	Jan 29 08:43 PM
Lamy Patrick	Senior VP, Commercial Strategy	Jan 27 '25	Sale	57.03	5,000	285,150	33,492	Jan 29 08:43 PM
Cheng Andrew	President and CEO	Jan 27 '25	Sale	54.90	30,000	1,646,978	716,062	Jan 29 08:43 PM
Young Jonathan	Chief Operating Officer	Jan 24 '25	Option Exercise	6.36	43,064	274,059	261,147	Jan 27 06:08 PM
Cheng Andrew	President and CEO	Jan 23 '25	Option Exercise	0.61	50,000	30,750	746,062	Jan 27 06:07 PM
CATRIONA YALE	Officer	Jan 27 '25	Proposed Sale	26.18	53,591	1,403,012		Jan 27 04:24 PM
CATRIONA YALE	Officer	Jan 27 '25	Proposed Sale	26.18	69,073	1,808,331		Jan 27 04:24 PM
PATRICK D LAMY	Officer	Jan 27 '25	Proposed Sale	26.18	6,000	157,080		Jan 27 04:23 PM
Andrew Cheng	President, CEO and Director	Jan 27 '25	Proposed Sale	57.03	120,000	6,843,600		Jan 27 04:19 PM
Timothy Rolph	Officer	Jan 27 '25	Proposed Sale	57.03	68,750	3,920,813		Jan 27 04:06 PM
Young Jonathan	Chief Operating Officer	Jan 02 '25	Sale	28.03	10,000	280,330	218,083	Jan 06 02:08 PM
Jonathan Young	Officer	Jan 02 '25	Proposed Sale	27.82	70,000	1,947,400		Jan 02 04:29 PM
Lamy Patrick	Senior VP, Commercial Strategy	Dec 16 '24	Sale	29.13	1,000	29,130	34,258	Dec 18 09:03 PM
Yale Catriona	Chief Development Officer	Dec 16 '24	Option Exercise	21.10	9,074	191,461	104,722	Dec 18 09:01 PM
Yale Catriona	Chief Development Officer	Dec 16 '24	Sale	29.11	9,074	264,117	95,648	Dec 18 09:01 PM
Rolph Timothy	Chief Scientific Officer	Dec 17 '24	Option Exercise	19.87	3,800	75,506	182,137	Dec 18 08:52 PM
Rolph Timothy	Chief Scientific Officer	Dec 17 '24	Sale	31.10	3,800	118,172	178,337	Dec 18 08:52 PM
PATRICK D LAMY	Officer	Dec 16 '24	Proposed Sale	28.89	1,000	28,890		Dec 16 04:30 PM
Rolph Timothy	Chief Scientific Officer	Dec 10 '24	Option Exercise	19.87	2,450	48,682	180,787	Dec 12 08:44 PM
Rolph Timothy	Chief Scientific Officer	Dec 10 '24	Sale	30.91	4,818	148,934	178,337	Dec 12 08:44 PM
Young Jonathan	Chief Operating Officer	Dec 10 '24	Sale	30.79	2,503	77,067	203,783	Dec 12 08:38 PM
Lamy Patrick	Senior VP, Commercial Strategy	Dec 10 '24	Sale	30.79	925	28,481	17,858	Dec 12 08:29 PM
Yale Catriona	Chief Development Officer	Dec 10 '24	Sale	30.79	2,810	86,520	71,348	Dec 12 08:28 PM
White William Richard	Chief Financial Officer	Dec 10 '24	Sale	30.79	2,817	86,735	38,335	Dec 12 08:26 PM
Cheng Andrew	President and CEO	Dec 10 '24	Sale	30.79	7,855	241,855	597,562	Dec 12 08:24 PM
Timothy Rolph	Officer	Dec 10 '24	Proposed Sale	30.79	25,000	769,750		Dec 10 04:25 PM
Cheng Andrew	President and CEO	Dec 02 '24	Option Exercise	21.10	25,000	527,500	630,417	Dec 04 07:36 PM
Cheng Andrew	President and CEO	Dec 02 '24	Sale	32.09	25,000	802,250	605,417	Dec 04 07:36 PM
Young Jonathan	Chief Operating Officer	Dec 02 '24	Sale	32.13	10,000	321,310	206,286	Dec 04 07:34 PM
Yale Catriona	Chief Development Officer	Nov 15 '24	Option Exercise	21.10	9,061	191,187	83,219	Nov 19 09:57 PM
Yale Catriona	Chief Development Officer	Nov 15 '24	Sale	27.73	9,061	251,274	74,158	Nov 19 09:57 PM
Yale Catriona	Chief Development Officer	Nov 06 '24	Option Exercise	0.61	10,000	6,150	84,158	Nov 08 05:06 PM
Yale Catriona	Chief Development Officer	Nov 06 '24	Sale	35.19	10,000	351,890	74,158	Nov 08 05:06 PM
CATRIONA YALE	Officer	Nov 06 '24	Proposed Sale	32.74	10,000	327,400		Nov 06 05:01 PM
Young Jonathan	Chief Operating Officer	Nov 01 '24	Option Exercise	21.09	40,716	858,700	267,002	Nov 05 09:04 AM
Young Jonathan	Chief Operating Officer	Nov 01 '24	Sale	31.57	50,716	1,601,252	216,286	Nov 05 09:04 AM
Cheng Andrew	President and CEO	Nov 01 '24	Option Exercise	21.10	108,366	2,286,523	686,697	Nov 05 09:00 AM
Cheng Andrew	President and CEO	Nov 01 '24	Sale	31.73	108,366	3,438,312	605,417	Nov 05 09:00 AM
Yale Catriona	Chief Development Officer	Nov 01 '24	Option Exercise	21.10	15,485	326,734	89,643	Nov 01 08:59 PM
Yale Catriona	Chief Development Officer	Oct 30 '24	Option Exercise	21.10	4,515	95,266	78,673	Nov 01 08:59 PM
Yale Catriona	Chief Development Officer	Nov 01 '24	Sale	32.62	15,485	505,105	74,158	Nov 01 08:59 PM
Yale Catriona	Chief Development Officer	Oct 30 '24	Sale	32.53	4,515	146,855	74,158	Nov 01 08:59 PM
CATRIONA YALE	Officer	Nov 01 '24	Proposed Sale	30.83	29,074	896,351		Nov 01 04:46 PM
Cheng Andrew	President and CEO	Oct 18 '24	Option Exercise	21.10	63,539	1,340,673	668,956	Oct 18 08:57 PM
Cheng Andrew	President and CEO	Oct 16 '24	Option Exercise	21.10	24,992	527,331	630,409	Oct 18 08:57 PM
Cheng Andrew	President and CEO	Oct 17 '24	Option Exercise	21.10	3,103	65,473	608,520	Oct 18 08:57 PM
Cheng Andrew	President and CEO	Oct 18 '24	Sale	31.53	63,539	2,003,328	605,417	Oct 18 08:57 PM
Cheng Andrew	President and CEO	Oct 16 '24	Sale	31.14	24,992	778,151	605,417	Oct 18 08:57 PM
Cheng Andrew	President and CEO	Oct 17 '24	Sale	31.12	3,103	96,559	605,417	Oct 18 08:57 PM
Young Jonathan	Chief Operating Officer	Oct 14 '24	Option Exercise	21.09	40,000	843,600	266,286	Oct 16 08:06 PM
Young Jonathan	Chief Operating Officer	Oct 14 '24	Sale	30.15	40,000	1,206,080	226,286	Oct 16 08:06 PM
Yale Catriona	Chief Development Officer	Oct 15 '24	Option Exercise	0.61	14,825	9,117	90,119	Oct 16 08:06 PM

EXEL

Exelixis Inc

AKRO

Akero Therapeutics Inc

Upgrade your FINVIZ experience